Biophore to Increase Favipiravir ProductionJul 14, 2020 11:12 AM
Indian Pharmaceuticals Biophore based in Telanagana Hyderabad had increased the production of Favipiravir. It is a vital ingredient that is used for the anti-viral drug. The drug is approved by Drug Controller General of India (DCGI) to deal with the mild symptom and moderate cases of Covid-19 virus. Biophore has a license from Drug Controller General of India (DCGI) to manufacture (Active pharmaceuticals ingredients) which in this case is Favipiravir. The Pharmaceuticals have not only received approval from India but also from a local partner in Turkey. The product will be commercialized in Egypt, Bangladesh. The Pharma is waiting for the DCGI approval for a Favipiravir in the form of dosage.
The Chief Scientific Officer Manik Reddy Pullagurla of Biophore said, “The Covid-19 pandemic has emphasized the need for pharmaceutical companies to step up and develop effective solutions quickly, without compromising on safety. We have ensured that our favipiravir meets the highest standards of quality.”
He also emphasized that they can upscale the production and supply locally as well as maintaining overseas demand. Favipiravir is an antiviral agent and it works effectively against influenza, and RNA virus. It is already approved in India and Turkey for Covid-19 and also in the Middle East and Russia.
It is a complete made in India and there are trials of advanced stage in various parts of the world.